Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Future Of Immune Checkpoint Therapy

P. Sharma, J. Allison
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.
This paper references
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
10.1038/nature00766
Mutations of the BRAF gene in human cancer
Helen Davies (2002)
10.1200/JCO.2013.31.15_SUPPL.3016
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
Joseph F. Grosso (2013)
10.1007/82_2010_114
LAG-3 in Cancer Immunotherapy.
Monica V. Goldberg (2011)
10.1158/0008-5472.CAN-13-1506
VISTA Regulates the Development of Protective Antitumor Immunity.
I. Le Mercier (2014)
10.1200/JCO.2014.32.15_SUPPL.5010
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
A. Amin (2014)
10.1158/1078-0432.CCR-12-1630
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
D. Frederick (2013)
10.1158/2326-6066.CIR-13-0031-T
Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
William L. Redmond (2013)
10.1056/NEJMoa1200694
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
10.1038/nature12477
Signatures of mutational processes in human cancer
L. Alexandrov (2013)
10.1016/S0140-6736(14)60958-2
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
C. Robert (2014)
10.1084/JEM.192.7.1027
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
10.1111/pcmr.12340
PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials
J. Madore (2015)
10.1001/jama.2014.13943
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
F. S. Hodi (2014)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
10.1200/JCO.2014.32.15_SUPPL.4504
Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
H. Hammers (2014)
10.1038/nature14011
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
R. Herbst (2014)
10.1038/nrc3153
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
P. Sharma (2011)
10.1158/2159-8290.CD-14-0863
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.
Nicolas J. Llosa (2015)
10.1073/PNAS.95.17.10067
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
A. Hurwitz (1998)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.1158/0008-5472.CAN-11-1620
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo (2012)
10.1200/JCO.2008.16.1927
Phase I/II study of ipilimumab for patients with metastatic melanoma.
J. Weber (2008)
10.1056/NEJMOA050092
Distinct sets of genetic alterations in melanoma.
J. A. Curtin (2005)
10.1056/NEJMoa1305133
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
10.1016/S1470-2045(12)70007-4
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
A. V. D. van den Eertwegh (2012)
10.1084/JEM.176.6.1595
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes
P. Linsley (1992)
10.1038/nrc3239
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
10.1146/ANNUREV.IMMUNOL.23.021704.115611
The B7 family revisited.
R. Greenwald (2005)
10.1158/1078-0432.CCR-10-0569
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
B. Carthon (2010)
10.1038/nm730
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
10.1038/nm1100
Cancer immunotherapy: moving beyond current vaccines
S. Rosenberg (2004)
10.1073/pnas.0915174107
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
M. Curran (2010)
10.1158/2326-6066.CIR-13-0020
Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
D. Ng Tang (2013)
10.1158/0008-5472.CAN-11-2637
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
J. Fourcade (2012)
10.1016/1074-7613(94)90071-X
CTLA-4 can function as a negative regulator of T cell activation.
T. Walunas (1994)
10.1126/science.aaa1348
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
N. Rizvi (2015)
10.1056/NEJMoa1406498
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
A. Snyder (2014)
10.1200/JCO.2014.56.2736
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
D. Schadendorf (2015)
10.1097/CJI.0b013e31829fb7a2
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
D. Le (2013)
10.1038/nature13954
PD-1 blockade induces responses by inhibiting adaptive immune resistance
P. Tumeh (2014)
10.1084/jem.20100619
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
10.1084/jem.20100643
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi (2010)
A. are founders and advisors for Jounce Therapeutics
10.1126/SCIENCE.7678351
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.
S. E. Townsend (1993)
10.1084/JEM.190.3.355
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
A. van Elsas (1999)
10.1097/CJI.0b013e318156e47e
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
J. Yang (2007)
10.4161/onci.19442
CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
R. Waitz (2012)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1056/NEJMoa1411087
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
S. Ansell (2015)
10.1038/mt.2014.160
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
C. E. Engeland (2014)
10.1084/jem.20100637
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients
J. Fourcade (2010)
10.1158/0008-5472.CAN-11-1138
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
T. Fu (2011)
10.1038/nri1111
The TIM gene family: emerging roles in immunity and disease
Vijay K. Kuchroo (2003)
10.1073/pnas.0806075105
CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
C. Liakou (2008)
10.1172/JCI73014
Targeting CD137 enhances the efficacy of cetuximab.
H. Kohrt (2014)
10.1126/SCIENCE.1840703
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
P. van der Bruggen (1991)
10.1084/jem.20130590
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
X. Fan (2014)
10.1056/NEJMoa1302369
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
10.1084/JEM.182.2.459
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
M. Krummel (1995)
10.1200/JCO.2014.32.3_SUPPL.148
Can induction chemotherapy improve dysphagia in locally advanced esophageal/GEJ cancer?
Elizabeth Won (2014)
10.1126/science.aaa4971
Neoantigens in cancer immunotherapy
T. Schumacher (2015)
10.1172/JCI40070
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
L. Derré (2010)
10.1073/pnas.0712237105
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. S. Hodi (2008)
10.1038/nature13904
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
T. Powles (2014)
10.1126/scitranslmed.3008095
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
D. Zamarin (2014)
10.1016/j.semradonc.2014.07.003
Current clinical trials testing combinations of immunotherapy and radiation.
M. Crittenden (2015)
10.1056/NEJMoa1412082
Nivolumab in previously untreated melanoma without BRAF mutation.
C. Robert (2015)
10.1084/JEM.171.5.1393
LAG-3, a novel lymphocyte activation gene closely related to CD4
F. Triebel (1990)
10.1158/2326-6066.CIR-14-0069
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Chad Tang (2014)



This paper is referenced by
10.1080/2162402X.2017.1295903
Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma
Abhishek D Garg (2017)
SELF-AMPLIFYING RNA VECTORS ENCODING SURVIVIN AS ANTI-TUMORAL VACCINE CANDIDATES Relatore: Prof. Diego Maria Michele FORNASARI Correlatore: Prof. Antonio SICCARDI Coordinatore del Dottorato: Prof. Massimo LOCATI
Degli Studi (2016)
10.1080/21645515.2016.1223000
Local delivery of checkpoints antibodies
C. Wang (2017)
Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression.
G. Koelwyn (2015)
10.1172/jci.insight.90201
C3d regulates immune checkpoint blockade and enhances antitumor immunity.
J. Platt (2017)
10.15406/MOJI.2016.03.00092
CTLA-4 Antibodies in Cancer Immunotherapy
Veerendra Koppolu (2016)
Oncolytic viruses armed with immunostimulatory genes for cancer treatment
Mantas Šilanskas (2018)
More efficient use of HER targeting agents in cancer therapy
Tiia Honkanen (2019)
A generic cell surface ligand system for studying cell#_#x2013;cell recognition
M. Eleanor (2019)
10.5772/INTECHOPEN.72648
Significance of Tumor Microenvironment Scoring and Immune Biomarkers in Patient Stratification and Cancer Outcomes
K. D. Alsibai (2018)
10.1158/1078-0432.CCR-19-0405
Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas
H. Jiang (2019)
10.1097/WCO.0000000000000686
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy
C. Perrinjaquet (2019)
10.18632/oncotarget.17702
A novel immunotherapy targeting MMP-14 limits hypoxia, immune suppression and metastasis in triple-negative breast cancer models.
B. Ling (2017)
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
M. Ayers (2020)
10.1080/00325481.2019.1709344
Immune checkpoint inhibitors and endocrine side effects, a narrative review
L. Agrawal (2019)
10.1007/978-3-319-99235-8_3
Global HIV/AIDS Burden and Associated Diseases
C. K. Williams (2019)
10.1038/ncomms13354
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju Yeon Lee (2016)
10.1158/0008-5472.CAN-17-0381
CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer.
W. He (2017)
10.1073/pnas.1917891117
Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy
G. Chen (2020)
10.1016/j.celrep.2016.05.058
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
Katelyn T. Byrne (2016)
10.1111/jdv.14179
Two cases of anti‐programmed cell death 1‐associated bullous pemphigoid‐like disease and eruptive keratoacanthomas featuring combined histopathology
J. P. Bandino (2017)
10.3390/s19245409
A Graphene-Based Glycan Biosensor for Electrochemical Label-Free Detection of a Tumor-Associated Antibody
Filip Kveton (2019)
10.3233/JND-200504
Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists.
L. Peverelli (2020)
10.1016/j.actbio.2019.03.048
Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy.
Zhuoya Wan (2019)
10.1186/s12967-016-0791-2
Melanoma and immunotherapy bridge 2015
V. G. Y. Nanda (2016)
10.1002/jgm.3088
Tumor microenvironment as the “regulator” and “target” for gene therapy
J. Wu (2019)
10.1002/jcp.27850
Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches
N. H. Goradel (2019)
10.1158/0008-5472.CAN-18-3208
Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
Huizhong Xiong (2019)
10.1016/j.smim.2019.101295
Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications.
Janna Krueger (2019)
10.1016/J.JINORGBIO.2019.02.004
Pt(IV) hybrids containing a TDO inhibitor serve as potential anticancer immunomodulators.
Shixian Hua (2019)
10.1038/s41571-018-0119-7
Time to abandon single-site irradiation for inducing abscopal effects
E. Brooks (2018)
10.1016/B978-0-12-804010-2.00005-9
Immunodeficient Mice: The Backbone of Patient-Derived Tumor Xenograft Models
D. Hirenallur-Shanthappa (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar